First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Press Release
SAN DIEGO, December 2, 2021 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN), and Sequoia Capital China, a leading investment firm, jointly announced the selection of the first two startup companies joining the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina. Located in Zhangjiang Cell Industrial Park, Shanghai, the incubator will serve as a company creation engine focused on supporting life sciences startup companies who are poised to deliver breakthrough applications in genomics and multiomics.
The iHope™ Genetic Health program will expand access to whole-genome sequencing to low- and middle-income communities around the world, with more than one-third of funds being allocated to patients in Africa
Press Release
SAN DIEGO, November 16, 2021 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) and Genetic Alliance today announced the creation of the iHope™ Genetic Health program aimed at providing whole-genome sequencing access (WGS) to tens of thousands of patients across the globe impacted by genetic disease. At least half of iHope Genetic Health’s efforts will be focused on areas of the world in need outside the US, with more than one-third of Illumina’s support being dedicated to patients in Africa.
This Veterans Day, we saluted employees like Martin Holguin, as he shared with us his personal journey from military service to civilian life as a Staff Program Manager of Manufacturing Technologies and Transfer here at Illumina.
We are proud to announce that for the first time, Illumina was named a Military Times Best for Vets Employer, coming in at #114 out of 160 companies selected.
The 2021 list includes companies that scored above 85% on topics such as general inclusive workplace policies; partnership with veteran owned businesses; and efforts to recruit, retain, and support current and former service members.
Data from 10,000 individuals affected by SARS-CoV-2 will be used to identify biomarkers that can help predict potential risk of serious disease and support the development of novel therapeutics to combat COVID-19
Press Release
SAN DIEGO, November 4, 2021 /3BL Media/ - Illumina Inc. (NASDAQ: ILMN) today announced that its world-class sequencing and bioinformatics solutions are being used by HostSeq, part of the Canadian COVID-19 Genomics Network (CanCOGeN), to identify biomarkers that can help predict potential risk of serious disease and support the development of novel therapeutics to combat COVID-19.
We are proud to announce that Illumina has been included in Forbes’ inaugural list highlighting the World’s Top Female Friendly Companies, ranking 11th out of the top 300 multinational corporations from over 40 countries.
On October 23, more than 30 Illumina employees and their families volunteered at Shanghai Chongming Dongtan Wetland Reserve, cleaning up marine litter and plastic bottles and learning about wetland biology and the severity of marine litter.
Illumina and the San Diego Zoo Wildlife Alliance swing for the treetops and try to preserve the species with the help of genomic data
Blog
In the 1960s, with the intent to conserve a rare species of primate, the San Diego Zoo initiated a successful breeding program with red ruffed lemurs (varecia rubra) from Madagascar. After the establishment of its in-house research effort, the Zoo also elected to freeze cells from that founding population and their descendants and store them in a facility called the Frozen Zoo.
Whole-genome sequencing (WGS) enables faster identification of disease-causing genetic abnormalities in infants improving clinical care and management
Press Release
SAN DIEGO, October 28, 2021 /3BL Media/ -- Illumina, Inc. (NASDAQ: ILMN) announced an agreement with Israel's Ministry of Health (MoH) for a pilot program to implement the use of whole-genome sequencing (WGS) in critically-ill infants suspected of having a genetic disorder in neonatal intensive care units (NICU).
